RecruitingNot ApplicableNCT06826066

Involvement of the Immune System in Intrinsic Radiosensitivity

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

40 participants

Start Date

May 12, 2025

Study Type

INTERVENTIONAL

Conditions

Neoplasms

Summary

Radiotherapy is one of the major treatments for cancer. It may be indicated in more than two-thirds of patients, regardless of cancer location or disease stage. The mechanisms of radiotherapy action are numerous: halting tumor proliferation, inducing tumor cell death, triggering anti-tumor immune responses, and ensuring both local and systemic tumor control. As a result, current treatments are highly effective, providing, for instance, a 5-year overall survival rate of about 90%-95% for localized breast and prostate cancers.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Age ≥ 18 years
Patients who have been treated with radiotherapy
Absence of toxicity grade 2 or higher
Patients without psychiatric, sociological, family, or geographical difficulties that could interfere with patient compliance to the protocol or follow-up
Information and signed informed consent
Affiliated with social security

Exclusion Criteria6

Inability to obtain patient consent
Patient refusing blood sample collection
Patient deprived of liberty or under legal protection (under guardianship, under curatorship)
Patients who have experienced radiation-induced toxicity of grade 2 or higher
Disease progression, relapse
Patient under State Medical Aid

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood samples

We propose to include patients who have been treated with radiotherapy and did not experience severe radiation-induced toxicity, after obtaining their informed consent. A blood sample will then be collected by the nursing staff from the Oncology-Radiotherapy department at Henri Mondor University Hospital. After the patient signs the consent form, each patient will have their clinical information recorded and a blood sample taken. The blood samples will be immediately transported, at room temperature, to the INSERM U955 i-Biot unit at Henri Mondor (serum, plasma, and PBMC). All samples will be frozen at -80°C for later analysis.